Fulcrum Therapeutics (FULC) AI Stock Analysis

• Market Cap: $364.04M
• Dividend Yield: N/A
• Average Volume (3M): 851.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: -100.00%
• EPS Growth: -266.37%
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 54,091,587
• 10 Day Avg. Volume: 1,382,727
• 30 Day Avg. Volume: 851,083
• PEG Ratio: <0.01
• Price to Book (P/B): 2.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.71
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.66
• 1Y Price Target: $9.86
• Price Target Upside: 44.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 60 Neutral
• Price Target: $7.50 ▲(9.81%Upside)

Fulcrum Therapeutics' overall stock score of 60.15 reflects a blend of strengths and challenges. The company's strong financial foundation and promising trial developments are counterbalanced by ongoing profitability issues and valuation concerns. The positive sentiment from recent earnings calls and corporate events supports future growth potential, but operational improvements are critical.

Positive Factors

Clinical Trial Results

FULC reported positive 12mg dose cohort data from the Phase 1b PIONEER study demonstrating encouraging efficacy across multiple metrics.

Investor Interest

There is growing investor interest in FULC’s oral small molecule approach, as exhibited by FULC’s recent strength.

Stock Performance

The stock has more room to run, especially with growing scarcity value in the SCD space.

Negative Factors

Patient Response

There is a downside risk that more therapy-unresponsive patients may not replicate the positive response seen in previous cohorts.

Safety Concerns

There are consistent concerns from doctors regarding the safety of pociredir, which caps the company's stock upside despite recent price increases.

Trial Eligibility

Fulcrum Therapeutics had to tighten its eligibility criteria for trials in response to FDA's clinical hold due to potential malignancy risks.

Fulcrum Therapeutics Business Overview & Revenue Model

Company Description

Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company dedicated to developing therapies that modulate gene expression to treat genetically defined rare diseases. The company focuses on innovative treatments for diseases with unmet medical needs, primarily targeting rare muscle disorders and other serious conditions. Fulcrum Therapeutics leverages its proprietary product engine, FulcrumSeek, to identify and validate drug targets that can precisely control gene expression pathways relevant to specific diseases.

How the Company Makes Money

Fulcrum Therapeutics generates revenue primarily through partnerships, collaborations, and the development of its proprietary drug candidates. The company's revenue model includes upfront payments, milestone payments, and royalties from strategic collaborations with larger pharmaceutical companies. These partnerships often involve joint research efforts, where Fulcrum provides its expertise in gene modulation and drug development while the partner contributes additional resources for clinical trials and commercialization. Fulcrum also aims to advance its own pipeline of drug candidates through clinical trials, seeking to bring therapies to market that could generate significant sales revenue upon regulatory approval.

Fulcrum Therapeutics Financial Statement Overview

Summary

Fulcrum Therapeutics shows strong revenue stability and a robust balance sheet with low leverage and high equity. However, the company struggles with operational profitability and cash flow sustainability due to consistent net losses. Improvement is needed in operational efficiencies to leverage financial strength into profitability.

Income Statement

Fulcrum Therapeutics shows a stable revenue over the TTM period with $80M, but the company is struggling with negative net income at -$510,000 and a significant negative EBIT margin of -15.58%. The company's gross profit margin is strong at 78.42%, indicating good cost control over production, but the high operating losses need addressing to improve profitability.

Balance Sheet

The balance sheet of Fulcrum Therapeutics is robust, with a high equity ratio of 94.15% and low debt-to-equity ratio of 0.04, indicating minimal reliance on debt. The company's stockholders' equity stands strong at $228.49M, providing a solid financial foundation. However, the company needs to focus on converting this equity strength into operational profitability.

Cash Flow

Fulcrum Therapeutics shows improvement in cash flow with a positive operating cash flow of $7.81M in the TTM period, turning around from previous negative cash flows. The free cash flow is also positive at $7.56M, indicating better cash management. However, the operating cash flow to net income ratio is not sustainable at 15.31 due to negative net income, which suggests future cash flow stability is uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	80.00M	2.81M	6.34M	19.16M	8.82M
Gross Profit	0.00	78.41M	2.81M	3.93M	16.65M	6.44M
EBITDA	-81.62M	-18.24M	-108.49M	-109.72M	-78.54M	-69.23M
Net Income	-73.22M	-9.72M	-97.33M	-105.62M	-78.33M	-68.44M
Balance Sheet
Total Assets	228.84M	260.72M	257.69M	226.69M	235.00M	129.58M
Cash, Cash Equivalents and Short-Term Investments	214.11M	241.02M	236.22M	202.92M	218.16M	112.91M
Total Debt	7.57M	8.63M	10.82M	13.42M	0.00	17.00K
Total Liabilities	14.46M	17.68M	22.50M	27.74M	23.46M	34.40M
Stockholders Equity	214.38M	243.03M	235.19M	198.94M	211.54M	95.18M
Cash Flow
Free Cash Flow	-65.22M	-2.50M	-91.47M	-99.01M	-80.19M	-55.00M
Operating Cash Flow	-64.91M	-2.22M	-90.97M	-97.05M	-78.48M	-53.66M
Investing Cash Flow	19.77M	32.23M	-36.69M	12.41M	-129.67M	-57.14M
Financing Cash Flow	1.02M	2.75M	118.12M	84.32M	186.51M	71.13M

Fulcrum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.83
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FULC, the sentiment is Neutral. The current price of 6.83 is below the 20-day moving average (MA) of 7.57, below the 50-day MA of 7.15, and above the 200-day MA of 4.64, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 12.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FULC.

Fulcrum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	69 Neutral	$152.39M	3.99	51.41%	―	-2.19%	34.91%
Sector *	60 Neutral	HK$16.95B	6.14	-7.34%	3.69%	12.24%	-25.44%
FULC	60 Neutral	$364.04M	―	-30.00%	―	-100.00%	-266.37%
TNGX	47 Neutral	$707.81M	―	-61.35%	―	10.10%	-7.25%
DSGN	47 Neutral	$216.86M	―	-22.59%	―	―	26.63%
IKT	46 Neutral	$117.46M	―	-79.02%	―	-100.00%	38.72%
DMAC	42 Neutral	$176.68M	―	-67.25%	―	―	2.53%

Fulcrum Therapeutics Corporate Events

Fulcrum Therapeutics Announces Promising Phase 1b Trial Results

On July 29, 2025, Fulcrum Therapeutics announced promising results from the 12 mg dose cohort of its Phase 1b clinical trial of pociredir for sickle cell disease. The trial showed significant increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia, with pociredir being well-tolerated and no serious adverse events reported. These findings suggest potential benefits in reducing vaso-occlusive crises and improving patient outcomes, positioning Fulcrum favorably in the biopharmaceutical industry. The company also reported a cash runway into 2028, despite a net loss in the second quarter of 2025.

The most recent analyst rating on (FULC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.

Fulcrum Therapeutics Elects New Directors at Annual Meeting

At the 2025 annual meeting held on June 26, Fulcrum Therapeutics‘ stockholders elected Katina Dorton, Robert Gould, and Kate Haviland as class III directors for a three-year term. Additionally, stockholders approved the compensation of the company’s named executive officers and decided on an annual frequency for future advisory votes on this matter. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions underscore Fulcrum’s commitment to maintaining strong governance and financial oversight, potentially enhancing stakeholder confidence.

The most recent analyst rating on (FULC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.